ADMA: a specific biomarker for pathologic progress in diabetic microvascular complications?

Area of Science:

• Biochemistry
• Endocrinology
• Vascular Biology

Background:

• Type 2 diabetes involves complex metabolic and angiopathic progressions.
• Glycated hemoglobin (HbA1c), asymmetric dimethylarginine (ADMA), and N-ϵ-(carboxymethyl)-lysine (CML) are implicated in diabetes progression.
• Identifying reliable biomarkers is crucial for understanding and managing diabetes complications.

Purpose of the Study:

• To evaluate HbA1c, ADMA, and CML as biomarkers in different stages of Type 2 diabetes.
• To identify a pathomechanism-based biomarker linked to metabolic and angiopathic progression.
• To determine the predictive value of these markers for early diabetic microvascular complications.

Main Methods:

• Analysis of peripheral blood samples from healthy volunteers, prediabetes, Type 2 diabetes, and early microvascular complication groups.
• Quantification of HbA1c, ADMA, and CML levels in collected samples.
• Statistical analysis including receiver operating characteristic (ROC) profiling to assess predictive accuracy.

Main Results:

• Asymmetric dimethylarginine (ADMA) demonstrated the strongest independent predictive power among the tested biomarkers.
• ADMA showed a significantly discriminative receiver operating characteristics profile.
• ADMA effectively distinguished individuals with early diabetic microvascular complications compared to HbA1c and CML.

Conclusions:

• Asymmetric dimethylarginine (ADMA) shows potential as a pathomechanism-based biomarker.
• ADMA may serve as a valuable tool for predicting the progression of diabetic microvascular complications.
• This finding supports the use of ADMA in clinical monitoring of diabetes patients.